Frequently Asked Questions
In 2022, the global Lung Biopsy Systems Market is expected to be worth USD 2451.6 million.
The Lung Biopsy Systems Market is estimated to increase at a CAGR of 9.80% between 2023 and 2030, reaching USD 5179.2 Million in 2030.
In 2022, hospitals had the largest market share
Percutaneous lung biopsy systems have a higher market demand
The market for ultrasound-guided biopsies is estimated to grow at the quickest CAGR throughout the forecast period
The North American lung biopsy systems market is estimated to account for 42% of the total by the end of 2035
The top players include Cardinal Health Inc., Becton Dickinson and Company, Olympus Corporation, Argon Medical Devices Inc., Hologic Inc.
The market is being driven by the rising frequency of lung disorders, advancements in biopsy methods, and an increase in demand for minimally invasive procedures.
The primary market limitations include the high cost of lung biopsy equipment, limited access to modern healthcare facilities in some countries, and stringent regulatory criteria for product approval.
Emerging markets with untapped potential, Technological innovations in lung biopsy systems and Collaborations and partnerships for research and development initiatives are the key opportunities of the market